Italia markets closed

Kala Pharmaceuticals, Inc. (0JQ2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
2,0350+0,1000 (+5,17%)
Alla chiusura: 6:59PM BST
Schermo intero
Chiusura precedente1,9350
Aperto1,8520
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,8520 - 2,0350
Intervallo di 52 settimane1,8520 - 2,0350
Volume5.762
Media VolumeN/D
Capitalizzazione47,468M
Beta (5 anni mensile)0,50
Rapporto PE (ttm)N/D
EPS (ttm)-2,1060
Prossima data utili03 nov 2021 - 08 nov 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 70,000 shares of Kala Pharmaceuticals common stock to ten new employees. The stock options were granted on October 18, 2021. The gr

  • GlobeNewswire

    Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

    WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the appointment of C. Daniel Myers to its Board of Directors. Mr. Myers, who has more than 35 years of ophthalmic pharmaceutical experience, will serve as a Class III director, and join both the Compensation and Nominating and Corporate

  • GlobeNewswire

    Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

    WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021: H.C. Wainwright 23rd Annual Global Investment ConferenceA pre-recorded presentation will be made available beginning Monday, S